Lifeward Ltd. Receives Nasdaq Non-Compliance Notice: Key Details for Investors

Summary of Key Points

• Nasdaq Non-Compliance Notice: Lifeward Ltd. has received a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with a corporate governance standard.
• Audit Committee Shortfall: The resignation of Hadar Levy from the Board of Directors reduced the Audit Committee to two members, violating Nasdaq Listing Rule 5605(c)(2)(A), which requires at least three members.
• Compliance Timeline: The company has until the earlier of its next annual shareholders’ meeting or February 24, 2027 to regain compliance, unless the next annual meeting is held before August 24, 2026, in which case compliance must be demonstrated by August 24, 2026.
• Immediate Impact: The notice does not immediately affect the listing of Lifeward’s ordinary shares, which continue to trade on Nasdaq Capital Market under the symbol “LFWD”.
• Uncertainty: There is no assurance that Lifeward will successfully regain compliance within the applicable cure period.

Detailed Analysis

On March 17, 2026, Lifeward Ltd. (formerly known as ReWalk Robotics Ltd. and Argo Medical Technologies Ltd.) received an Audit Committee Notice from the Nasdaq Listing Qualifications Department. This notice follows the resignation of Hadar Levy from the Board of Directors, which reduced the company’s Audit Committee to two members. According to Nasdaq Listing Rule 5605(c)(2)(A), listed companies are required to maintain an audit committee of at least three members. With only two members, Lifeward is now out of compliance with this governance standard.

The company is currently reviewing and evaluating potential options to regain compliance. According to Nasdaq Listing Rule 5605(c)(4), Lifeward must cure the deficiency by the earlier of its next annual shareholders’ meeting or February 24, 2027. If the next annual meeting occurs before August 24, 2026, compliance must be restored by that date. This provides a window of opportunity for the company to address the issue, but also introduces uncertainty.

For investors and shareholders, this notice is potentially price-sensitive: Corporate governance deficiencies, especially those related to audit committees, are viewed seriously by exchanges and market participants. Such notices can impact investor confidence and, in turn, share price. While the company’s shares continue to trade on the Nasdaq Capital Market under the ticker “LFWD”, failure to cure the deficiency could ultimately risk delisting.

Lifeward has stated that the Audit Committee Notice does not have an immediate effect on the listing of its ordinary shares. The shares will continue to trade as usual while the company works toward regaining compliance. However, investors should closely monitor further developments, including any board appointments, annual meeting dates, and updates on compliance efforts, as these could materially affect the company’s market status and share value.

Additional Information

• Company Details: Lifeward Ltd. is headquartered at 200 Donald Lynch Blvd., Marlborough, MA 01752, with business phone +1 508-251-1154.
• Registered Security: Ordinary Shares, par value NIS 0.25, trading symbol LFWD, listed on Nasdaq Capital Market.
• Emerging Growth Company: Lifeward is not classified as an emerging growth company under SEC rules.
• Chief Financial Officer: Almog Adar signed the report as CFO.

What Shareholders Should Watch

• Progress toward regaining compliance with Nasdaq Listing Rules.
• Any new appointments to the Audit Committee or Board of Directors.
• Timing of the next annual shareholders’ meeting.
• Potential impacts on share liquidity and exchange listing status.

Disclaimer

This article is based on current public filings and information as of March 20, 2026. It is intended for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with financial professionals before making investment decisions. The company’s future actions, market conditions, and regulatory responses may materially affect the outcome and share price.

View Lifeward Ltd. Historical chart here